Drug Comparison
For educational purposes only — a decision-support tool, not a substitute for clinical judgment.
Side-by-side rubric across 96 psychiatric medications. Every rating traces to a verbatim primary-source quote — click any cell to see it.
How to read this tool ▾
Rating scale
– Favorable / lower than class baseline
± Minimal / equivocal
+ Low / uncommon
++ Moderate / common
+++ High / very common
++++ Very high / class-outlier
Frequency vs severity
F = frequency, S = severity. Each gets its own pill colored on the same traffic-light scale: green → blue → yellow → orange → red. Click any cell for incidence percentages and NNH.
Evidence tier
A Network meta-analysis / RCT / FDA label
B Cohort / registry / pooled label data
C Expert review / textbook / case series
Sourcing
Click any cell to see the verbatim source quote and citation. Missing data shows n/a.
Data depth
++ Graded — frequency + severity, primary-source traces
+ FDA label — §6 frequency only (dashed border). Click for sub-types.
Blank — not yet checked (not “absent”)
–±++++++++++ABCF = frequency · S = severity · Dashed border = FDA label only · Click cell for details
1 drug selected — Ziprasidone(click to collapse)
1/4 selected
Ziprasidone
Geodon
Second-Generation Antipsychotic
FDA-approved indications
- Schizophrenia (adults)
- Acute mania/mixed episodes in Bipolar I — monotherapy (adults)
- Bipolar I maintenance — adjunct to lithium/valproate (adults)
- Acute agitation in schizophrenia (IM, adults)
Off-label uses
- Agitation in dementia
- Bipolar depression
- Treatment-resistant depression (adjunct)
Half-life7 hours
Decision GuideWhen to pick each / when to consider an alternative
Ziprasidone
Consider when
- Weight gain or metabolic syndrome at baseline — lowest weight change (−0.28 kg) and minimal metabolic impact among SGAs in Huhn NMA
- Hyperprolactinemia concern — near-placebo prolactin elevation (+1.18 ng/mL, NS); low sexual dysfunction (OR 0.64)
- Minimal CYP interaction burden — two-thirds metabolized by aldehyde oxidase; avoids CYP2D6/3A4 complications of most SGAs
- Anxiety comorbidity — 5-HT1A/1D partial agonist affinity contributes anxiolytic properties; unique receptor profile among SGAs
- +1 more
Consider an alternative when
- QTc risk factors present — among highest QTc-prolonging SGAs; baseline and follow-up ECGs required
- Inconsistent food intake — must take with ≥500 kcal meal; bioavailability drops 2–3× fasting
- BID dosing is an adherence barrier — short t½ requires twice-daily dosing; no LAI formulation available
- Concomitant QT-prolonging medications — thiazides, loop diuretics, or other QTc-prolonging agents amplify risk
- +1 more
| Axis | Ziprasidone SGA |
|---|---|
| Boxed Warnings | |
Suicidality (boxed warning) | |
Agranulocytosis / severe neutropenia | |
Cerebrovascular events (elderly w/ dementia) | |
Neuroleptic malignant syndrome (NMS) | |
DRESS / multiorgan hypersensitivity | |
| CNS | |
Sedation / somnolence | |
Activation / insomnia | |
Akathisia / EPS | |
Tardive dyskinesia | |
Seizure risk | |
| Metabolic | |
Weight gain | |
Metabolic (glucose / lipids) | |
| Endocrine | |
Prolactin elevation | |
| Autonomic | |
Anticholinergic burden | |
Orthostatic hypotension | |
| Cardiac | |
QTc prolongation | |
| GI | |
Nausea / GI (general) | |
| Dermatologic | |
Rash (including SJS/TEN, pruritus, hypersensitivity) | |
| Sexual | |
Sexual dysfunction | |
| Interactions | |
CYP interactions / DDI profile | |